Intra-arterial injection of fillers can lead to occlusion of the ophthalmic artery or its branches supplying the retina or the optic nerve. The mechanism through which this occurs is incompletely understood. We investigated the possibility of generating microparticles after injecting commercially available fillers into a flowing system in vitro.
Three hyaluronic acid fillers and one calcium hydroxylapatite filler were injected into an artificial saline flow system mimicking arterial systolic blood pressure and corresponding to the diameter of the facial artery. All the saline at the end of the tube was collected, centrifuged, and inspected for filler particles.
After injection into the system, all fillers immediately disintegrated into small particles that were carried downstream with the flow of the saline. The saline at the end of the tube contained collections of filler.
Hyaluronic acid and hydroxylapatite fillers break up into small particles immediately after injection into a flowing system, generating emboli rather than a column of filler. The results of this study lead us to hypothesize another potential mechanism leading to filler-related blindness.
Hyaluronic acid and hydroxylapatite fillers break up into small particles immediately after injection into a flowing system, generating emboli rather than a column of filler. The results of this study lead us to hypothesize another potential mechanism leading to filler-related blindness.We evaluated the morbidity and mortality after anatomical hepatectomy with the Glissonean pedicle approach, and long-term outcomes in relation to the morbidity in patients with hepatocellular carcinoma (HCC).
The mortality, morbidity, and long-term outcomes were evaluated retrospectively.
1953 patients with HCC underwent various anatomical hepatectomies with the Glissonean pedicle approach between 1985 and 2014. The mortality (30-day and 90-day) and morbidity (Clavien-Dindo class IIIa or higher) were evaluated among six 5-year eras (1985-1989, 1990-1994, 1995-1999, 2000-2004, 2005-2009, 2010-2014).
460 patients (24%) showed morbidity, and the overall 30-day and 90-day mortality rates were 1.8% and 3.3%, respectively. The 30-day (3.9%, 3.0%, 1.8%, 1.3%, 0.3%, 0.5% p = 0.0074) and 90-day mortality (6.0%, 4.3%, 3.8%, 2.8%, 2.2%, 1.4% p = 0.0445) significantly improved over the eras. Blood loss &gt;2 L (Odd ratio 11.808, p = 0.0244) was an independent risk factor for 30-day mortality, and blood loss &gt;2 L (Odd ratio 4.046, p = 0.0271) and bile leakage (Odd ratio 2.122, p = 0.0078) were independent risk factors for 90-day mortality on multivariate analysis. Morbidity was significant independent prognostic factors for overall survival (Relative Risk 2.129, p &lt; 0.0001) and recurrence-free survival (Relative Risk 1.299, p &lt; 0.0001) in patients with HCC.
Anatomical hepatectomy with the Glissonean pedicle approach was achieved safely in patients with HCC. For more safety and longer survival, blood loss, bile leakage, and morbidity should be reduced. Long-term outcomes after anatomical hepatectomy with the Glissonean pedicle approach in patients with HCC have been improved over 30 years with gradually less mortality and morbidity due to decreases in blood loss&gt;2L and bile leakage.
2L and bile leakage.This study assesses how the volume of pancreatic-adjacent operations (PAO) impacts the outcomes of pancreaticoduodenectomy (PD).
It is well-established that regionalization benefits outcomes after PD. However, due to a multitude of factors, including geographic, financial and personal, not all patients receive their care at high-volume pancreas surgery centers.
The National Cancer Database was queried for pancreatic cancer patients who underwent pancreaticoduodenectomy. Hospital volume was calculated for PD and PAO (defined as gastric, hepatic, complex biliary, or pancreatic operations other than PD) and dichotomized as low- and high-volume centers based on the median. Three study cohort were created low-volume hospitals (LVH) for both PD and PAO, mixed-volume hospital (MVH) with low-volume PD but high-volume PAO, and high-volume PD hospital (HVH).
In total, 24,572 patients were identified, with 41.5%, 7.2%, and 51.3% patients treated at LVH, MVH, and HVH, respectively. 30-day mortality for PD was 5.6% in LVH, 3.2% in MVH, and 2.5% in HVH. https://www.selleckchem.com/products/n-nitroso-n-methylurea.html On multivariable analyses, LVH was predictive for higher 30-day mortality compared to HVH (OR, 2.068; 95% CI, 1.770-2.418; p &lt; 0.0001). However, patients at MVH demonstrated similar 30-day mortality to patients treated at HVH (OR, 1.258; 95% CI, 0.942-1.680; p = 0.1203).
PD outcomes at low-volume centers that have experience with complex cancer operations near the pancreas are similar to PD outcomes at hospitals with high PD volume. MVH provide a model for PD outcomes to improve quality and access for patients who cannot, or choose not to, receive their care at high-volume centers.
PD outcomes at low-volume centers that have experience with complex cancer operations near the pancreas are similar to PD outcomes at hospitals with high PD volume. MVH provide a model for PD outcomes to improve quality and access for patients who cannot, or choose not to, receive their care at high-volume centers.To study the efficacy of liposomal bupivacaine on postoperative opioid requirement and pain following abdominal wall reconstruction.
Despite the widespread use of liposomal bupivacaine in transversus abdominis plane block, there is inadequate evidence demonstrating its efficacy in open abdominal wall reconstruction. We hypothesized that liposomal bupivacaine plane block would result in decreased opioid requirements compared to placebo in the first 72?hours after surgery.
This was a single-center double-blind, placebo-controlled prospective study conducted between July 2018 and November 2019. Adult patients (at least 18 years of age) undergoing open, elective, ventral hernia repairs with mesh placed in the retromuscular position were enrolled. Patients were randomized to surgeon-performed transversus abdominis plane block with liposomal bupivacaine, simple bupivacaine, or normal saline (placebo). The main outcome was opioid requirements in the first 72?hours after surgery. Secondary outcomes included total inpatient opioid use, pain scores determined using a 100?mm visual analog scale, length of hospital stay, and patient-reported quality of life.